Other languages Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
9.8 ^USD	+0.82%		-3.83%	+30.18%

30/04	HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target	MT
29/04	Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adverum Biotechnologies Files $200 Million Mixed Shelf	22/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	08/02
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	05/02
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	29/01
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors	06/11
Adverum Biotechnologies Announces Three-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023	05/11
Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial	27/23/27
Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer	22/23/22
Sector Update: Health Care Stocks Steady Premarket Friday	11/23/11
Adverum Biotechnologies Completes Enrollment in Mid-Stage Wet AMD Trial, Narrows Q2 Loss	11/23/11
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD	11/23/11
Adverum Biotechnologies Says it Licensed Ray Therapeutics for Gene Therapy Platform	12/23/12
Insider Buy: Adverum Biotechnologies	10/23/10
Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer	25/23/25
Adverum Biotechnologies Presents Data on Intravitreal Gene Therapy Program for Eye Disease	18/23/18
Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting	18/23/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Other languages

Filters